SCHEMBL22982883

SCHEMBL22982883

O=C(OCCC[C@@H]1CCCN(C(=O)O)C1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.50
SCN1A P35498 1/20 0.50
SCN2A Q99250 1/20 0.50
SCN3A Q9NY46 1/20 0.50
CHRNB2 P17787 3/20 0.46
CHRNA4 P43681 3/20 0.46
CHRNA5 P30532 1/20 0.46
CHRNA7 P36544 1/20 0.46
CHRM2 P08172 4/20 0.45
CHRM4 P08173 4/20 0.45
CHRM5 P08912 4/20 0.45
CHRM1 P11229 4/20 0.45
CHRM3 P20309 4/20 0.45
BCHE P06276 2/20 0.45
RAB9A P51151 1/20 0.44
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
LMNA P02545 1/20 0.41
ALDH1A1 P00352 2/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22982640 1.00 TDP1 (0.50) TDP1SCN1ASCN2ASCN3ACHRNB2
SCHEMBL23006166 0.87 ACKR3 (0.51) SCN1ASCN2ASCN3ACHRM2CHRM4
SCHEMBL28771668 0.87 ACKR3 (0.51) SCN1ASCN2ASCN3ACHRM2CHRM4
SCHEMBL22983598 0.87 ACKR3 (0.51) SCN1ASCN2ASCN3ACHRM2CHRM4
SCHEMBL3356243 0.81 TEAD3 (0.47) CHRNB2CHRNA4RAB9A
SCHEMBL3356236 0.81 TEAD3 (0.47) CHRNB2CHRNA4RAB9A
SCHEMBL3356619 0.81 TEAD3 (0.47) CHRNB2CHRNA4RAB9A
SCHEMBL4166609 0.78 KMT2A (0.56) BCHELMNAALDH1A1MAPT
SCHEMBL21820641 0.76 TDP1 (0.71) TDP1SCN1ASCN2ASCN3ABCHE
SCHEMBL30763608 0.74 EPHX2 (0.41) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013759-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2022-06-22 EP disclosed
WO-2021030556-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-02-18 WO disclosed